3billion Reports KRW 11.4 Billion in Revenue Through Q3 2026, Up 45.1% YoY

• Third-quarter revenue reached KRW 4.2 billion, and the operating loss narrowed by 25.9% from the previous quarter.
• 3billion recorded its first revenue from 3B-NEO and expanded its newborn testing business in the Philippines and the Dominican Republic.
• 3billion uses genomic data from approximately 118,000 individuals to improve AI diagnostics and guide therapeutic target discovery.

SEOUL, South Korea, November 13, 2026 — 3billion, Inc., an AI-powered genetic diagnostics and drug discovery company, today announced consolidated revenue of KRW 11.4 billion through Q3 2026, up 45.1% year over year.

Third-quarter revenue reached KRW 4.2 billion, up 30.0% year over year and 10.7% from the previous quarter. The operating loss narrowed by 25.9% from the previous quarter to KRW 1.2 billion. Through Q3 2026, operating loss as a share of revenue fell by 21.6 percentage points, from 61.8% a year earlier to 40.2%, even as R&D expenses, including spending on AI drug discovery, rose approximately 36% year over year to KRW 3.4 billion.

Net income through Q3 2026 was KRW 2.5 billion. This figure reflects non-cash valuation gains and losses related to convertible bonds and convertible preferred shares.

◼ Continued Growth in Rare Disease Genetic Testing and First Revenue from 3B-NEO

Through Q3 2026, revenue from 3billion’s rare disease genetic testing services, which use whole-exome sequencing (WES) and whole-genome sequencing (WGS), rose 46.8% year over year to KRW 9.9 billion. These services accounted for 87.2% of total revenue. International revenue for the same period was approximately KRW 7.8 billion, or 68.7% of total revenue.

3billion provides AI-powered genetic testing for rare diseases and offers GEBRA, its AI-based variant interpretation platform, as software as a service (SaaS). Healthcare institutions can order end-to-end testing from 3billion, with a workflow that covers sample collection, sequencing, variant interpretation and reporting. Institutions that already have genomic data can subscribe to GEBRA to interpret variants in-house. GEBRA’s international customer base has grown steadily, and healthcare institutions in around 40 countries now use the platform.

3billion recorded its first revenue from 3B-NEO in Q3 after launching the newborn screening service for international customers in June. In the United States and Europe, large-scale studies and pilot programs are evaluating genomic newborn screening (gNBS) in healthy newborns.

3billion is expanding its newborn testing business in Southeast Asia and Latin America, where birth rates are relatively high and adoption of gNBS is still in its early stages. In the Philippines, the company won contracts in the first two rounds of a public-sector pilot program that supports confirmatory genomic testing for newborns with abnormal initial screening results. In the Dominican Republic, 3billion signed an agreement to supply 3B-NEO to a local healthcare institution, laying the groundwork for additional sales.

◼ Genomic Data from 118,000 Individuals…A Key Competitive Advantage in Advancing AI Diagnostics

By the end of Q3 2026, 3billion had collected genomic data from approximately 118,000 individuals through its rare disease genetic testing services. The company uses these data alongside phenotypic information, including clinical symptoms, to refine its AI models for variant interpretation and automate more steps in the testing process.

3billion also uses genetic evidence from its diagnostic work in drug discovery. Earlier this month, the company signed a research collaboration agreement with DeepLife, a French AI drug discovery company. The two companies plan to identify therapeutic targets using genomic data and use DeepLife’s AI virtual cell platform, TwinCell, to study how those targets act in cells. The findings will inform the design of drug candidates.

“We grew revenue and reduced operating losses as a share of sales while increasing R&D investment to strengthen our competitive position in diagnostics and advance AI-driven drug discovery,” said Changwon Keum, CEO of 3billion. “We will continue to grow our genetic diagnostics business and work with international research partners to identify promising drug candidates. Through these collaborations, we will apply the genomic data and AI technologies behind our diagnostics to the development of new treatments.”